Strs Ohio boosted its position in shares of Blueprint Medicines Corporation (NASDAQ:BPMC) by 12.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,900 shares of the biotechnology company’s stock after buying an additional 2,600 shares during the period. Strs Ohio’s holdings in Blueprint Medicines Corporation were worth $1,160,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. UBS Asset Management Americas Inc. purchased a new stake in Blueprint Medicines Corporation during the first quarter worth approximately $201,000. Trexquant Investment LP purchased a new stake in Blueprint Medicines Corporation during the first quarter worth approximately $230,000. Legal & General Group Plc raised its stake in Blueprint Medicines Corporation by 31.8% in the first quarter. Legal & General Group Plc now owns 5,884 shares of the biotechnology company’s stock worth $235,000 after buying an additional 1,419 shares in the last quarter. AQR Capital Management LLC purchased a new stake in Blueprint Medicines Corporation during the fourth quarter worth approximately $289,000. Finally, Russell Investments Group Ltd. purchased a new stake in Blueprint Medicines Corporation during the fourth quarter worth approximately $305,000. 88.90% of the stock is currently owned by institutional investors.

Blueprint Medicines Corporation (NASDAQ:BPMC) opened at 46.11 on Monday. The company’s market capitalization is $1.80 billion. The company’s 50-day moving average is $51.90 and its 200 day moving average is $42.60. Blueprint Medicines Corporation has a 52 week low of $23.71 and a 52 week high of $56.81.

Blueprint Medicines Corporation (NASDAQ:BPMC) last issued its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.86) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.75) by $0.11. The company had revenue of $5.89 million for the quarter, compared to analysts’ expectations of $5.96 million. Blueprint Medicines Corporation had a negative net margin of 388.91% and a negative return on equity of 45.58%. The firm’s revenue for the quarter was down 16.7% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.70) earnings per share. On average, analysts forecast that Blueprint Medicines Corporation will post ($3.59) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Strs Ohio Has $1.16 Million Position in Blueprint Medicines Corporation (BPMC)” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/14/strs-ohio-has-1-16-million-position-in-blueprint-medicines-corporation-bpmc.html.

A number of equities research analysts have recently commented on the stock. Cowen and Company reaffirmed a “buy” rating on shares of Blueprint Medicines Corporation in a research note on Tuesday, June 6th. Zacks Investment Research lowered shares of Blueprint Medicines Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, April 18th. BidaskClub raised shares of Blueprint Medicines Corporation from a “hold” rating to a “buy” rating in a research note on Tuesday, June 20th. Wedbush reissued an “outperform” rating and set a $55.00 target price on shares of Blueprint Medicines Corporation in a research note on Tuesday, June 6th. Finally, Jefferies Group LLC increased their target price on shares of Blueprint Medicines Corporation from $42.00 to $52.00 and gave the stock a “buy” rating in a research note on Thursday, May 4th. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $47.90.

In other news, insider Anthony L. Boral sold 5,000 shares of the business’s stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $48.60, for a total transaction of $243,000.00. Following the sale, the insider now owns 5,000 shares in the company, valued at approximately $243,000. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Kate Haviland sold 6,357 shares of the business’s stock in a transaction on Wednesday, June 28th. The shares were sold at an average price of $50.00, for a total transaction of $317,850.00. Following the sale, the insider now owns 6,357 shares in the company, valued at approximately $317,850. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 128,622 shares of company stock worth $6,484,605. Company insiders own 3.40% of the company’s stock.

Blueprint Medicines Corporation Company Profile

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.

Want to see what other hedge funds are holding BPMC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Blueprint Medicines Corporation (NASDAQ:BPMC).

Institutional Ownership by Quarter for Blueprint Medicines Corporation (NASDAQ:BPMC)

Receive News & Stock Ratings for Blueprint Medicines Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corporation and related stocks with our FREE daily email newsletter.